IL102929A - Serum-free medium for mammalian cells - Google Patents

Serum-free medium for mammalian cells

Info

Publication number: IL102929A
Authority: IL; Israel
Prior art keywords: thrombin; medium according; medium; production; insulin
Prior art date: 1992-08-24

Application number

IL10292992A

Other languages

English (en)

Other versions

IL102929A0 (en

Original Assignee

Interpharm Lab Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-24

Filing date

1992-08-24

Publication date

1996-11-14

1992-08-24 Application filed by Interpharm Lab Ltd filed Critical Interpharm Lab Ltd

1992-08-24 Priority to IL10292992A priority Critical patent/IL102929A/en

1993-01-31 Publication of IL102929A0 publication Critical patent/IL102929A0/xx

1993-08-23 Priority to CA 2104643 priority patent/CA2104643C/fr

1993-08-23 Priority to JP20805393A priority patent/JP4124493B2/ja

1993-08-24 Priority to DK00117026T priority patent/DK1045023T3/da

1993-08-24 Priority to EP19930113502 priority patent/EP0584788B1/fr

1993-08-24 Priority to PT93113502T priority patent/PT584788E/pt

1993-08-24 Priority to DE1993634097 priority patent/DE69334097T2/de

1993-08-24 Priority to PT00117026T priority patent/PT1045023E/pt

1993-08-24 Priority to ES93113502T priority patent/ES2185618T3/es

1993-08-24 Priority to EP20000117026 priority patent/EP1045023B1/fr

1993-08-24 Priority to AT93113502T priority patent/ATE226632T1/de

1993-08-24 Priority to ES00117026T priority patent/ES2274756T3/es

1993-08-24 Priority to DK93113502T priority patent/DK0584788T3/da

1993-08-24 Priority to AT00117026T priority patent/ATE348147T1/de

1993-08-24 Priority to US08/111,428 priority patent/US5641647A/en

1993-08-24 Priority to AU44871/93A priority patent/AU670957B2/en

1993-08-24 Priority to ZA936192A priority patent/ZA936192B/xx

1993-08-24 Priority to DE69332430T priority patent/DE69332430T2/de

1996-11-14 Publication of IL102929A publication Critical patent/IL102929A/en

2007-02-09 Priority to CY0700004A priority patent/CY2572B1/xx

Links

239000012679 serum free medium Substances 0.000 title claims abstract description 35
210000004962 mammalian cell Anatomy 0.000 title claims abstract description 16
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 88
108090000190 Thrombin Proteins 0.000 claims abstract description 66
229960004072 thrombin Drugs 0.000 claims abstract description 66
239000002609 medium Substances 0.000 claims abstract description 57
238000004519 manufacturing process Methods 0.000 claims abstract description 53
102000004877 Insulin Human genes 0.000 claims abstract description 44
108090001061 Insulin Proteins 0.000 claims abstract description 44
229940125396 insulin Drugs 0.000 claims abstract description 44
230000003833 cell viability Effects 0.000 claims abstract description 8
239000011814 protection agent Substances 0.000 claims abstract description 6
210000004027 cell Anatomy 0.000 claims description 30
108090000623 proteins and genes Proteins 0.000 claims description 27
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 24
108090000166 Thrombin receptors Proteins 0.000 claims description 23
102000003790 Thrombin receptors Human genes 0.000 claims description 23
102000004169 proteins and genes Human genes 0.000 claims description 19
108090000765 processed proteins & peptides Proteins 0.000 claims description 18
108090001005 Interleukin-6 Proteins 0.000 claims description 17
239000012190 activator Substances 0.000 claims description 17
235000018102 proteins Nutrition 0.000 claims description 16
239000000047 product Substances 0.000 claims description 11
108010009736 Protein Hydrolysates Proteins 0.000 claims description 10
239000000413 hydrolysate Substances 0.000 claims description 8
150000001413 amino acids Chemical group 0.000 claims description 7
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 claims description 6
108010068370 Glutens Proteins 0.000 claims description 6
240000008042 Zea mays Species 0.000 claims description 6
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 6
235000002017 Zea mays subsp mays Nutrition 0.000 claims description 6
235000005822 corn Nutrition 0.000 claims description 6
235000021312 gluten Nutrition 0.000 claims description 6
239000003531 protein hydrolysate Substances 0.000 claims description 6
102000004407 Lactalbumin Human genes 0.000 claims description 5
108090000942 Lactalbumin Proteins 0.000 claims description 5
239000000203 mixture Substances 0.000 claims description 5
229920000609 methyl cellulose Polymers 0.000 claims description 4
239000001923 methylcellulose Substances 0.000 claims description 4
235000010981 methylcellulose Nutrition 0.000 claims description 4
238000010188 recombinant method Methods 0.000 claims description 4
108090000467 Interferon-beta Proteins 0.000 claims description 3
OXHYRVSBKWIFES-WWSDOYNLSA-N trap-14 peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 OXHYRVSBKWIFES-WWSDOYNLSA-N 0.000 claims description 3
HAGOWCONESKMDW-FRSCJGFNSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 HAGOWCONESKMDW-FRSCJGFNSA-N 0.000 claims description 2
102000003996 Interferon-beta Human genes 0.000 claims description 2
239000012980 RPMI-1640 medium Substances 0.000 claims description 2
108010086078 Ser-Phe-Phe-Leu-Arg-Asn Proteins 0.000 claims description 2
229960001388 interferon-beta Drugs 0.000 claims description 2
108010016851 thrombin receptor peptide (42-55) Proteins 0.000 claims description 2
102000004889 Interleukin-6 Human genes 0.000 claims 1
101710096655 Probable acetoacetate decarboxylase 1 Proteins 0.000 claims 1
229940100601 interleukin-6 Drugs 0.000 claims 1
102000019506 tumor necrosis factor binding proteins Human genes 0.000 claims 1
108091016215 tumor necrosis factor binding proteins Proteins 0.000 claims 1
230000000694 effects Effects 0.000 description 19
230000017306 interleukin-6 production Effects 0.000 description 14
230000010261 cell growth Effects 0.000 description 12
239000000654 additive Substances 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
239000013587 production medium Substances 0.000 description 7
239000004017 serum-free culture medium Substances 0.000 description 7
241000283690 Bos taurus Species 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
239000000969 carrier Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000013028 medium composition Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
239000013589 supplement Substances 0.000 description 4
102000004506 Blood Proteins Human genes 0.000 description 3
108010017384 Blood Proteins Proteins 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
238000010367 cloning Methods 0.000 description 3
238000012258 culturing Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
239000012634 fragment Substances 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000012913 medium supplement Substances 0.000 description 3
230000007017 scission Effects 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
101001011741 Bos taurus Insulin Proteins 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
102000016359 Fibronectins Human genes 0.000 description 2
101000976075 Homo sapiens Insulin Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
108010094028 Prothrombin Proteins 0.000 description 2
102100027378 Prothrombin Human genes 0.000 description 2
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
108091022873 acetoacetate decarboxylase Proteins 0.000 description 2
230000004913 activation Effects 0.000 description 2
229940049595 antibody-drug conjugate Drugs 0.000 description 2
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 2
230000032823 cell division Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
210000004897 n-terminal region Anatomy 0.000 description 2
230000008569 process Effects 0.000 description 2
229940039716 prothrombin Drugs 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
102100026720 Interferon beta Human genes 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
229940122388 Thrombin inhibitor Drugs 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
SRBFZHDQGSBBOR-KKQCNMDGSA-N beta-D-xylose Chemical class O[C@@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KKQCNMDGSA-N 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011143 downstream manufacturing Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
239000004744 fabric Substances 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
235000021095 non-nutrients Nutrition 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
230000010118 platelet activation Effects 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
-1 polypropylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229940082569 selenite Drugs 0.000 description 1
MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
239000012090 serum-supplement Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960003766 thrombin (human) Drugs 0.000 description 1
239000003868 thrombin inhibitor Substances 0.000 description 1
238000001890 transfection Methods 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000014616 translation Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/76—Undefined extracts from plants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL10292992A 1992-08-24 1992-08-24 Serum-free medium for mammalian cells IL102929A (en)

Priority Applications (19)

Application Number	Priority Date	Filing Date	Title
IL10292992A IL102929A (en)	1992-08-24	1992-08-24	Serum-free medium for mammalian cells
CA 2104643 CA2104643C (fr)	1992-08-24	1993-08-23	Milieu sans serum
JP20805393A JP4124493B2 (ja)	1992-08-24	1993-08-23	無血清培地
DE69332430T DE69332430T2 (de)	1992-08-24	1993-08-24	Serumfreies Medium für Säugetierzellen
ES93113502T ES2185618T3 (es)	1992-08-24	1993-08-24	Medio exento de suero para celulas de mamifero.
DK93113502T DK0584788T3 (da)	1992-08-24	1993-08-24	Serumfrit medium til mammale celler
PT93113502T PT584788E (pt)	1992-08-24	1993-08-24	Meio livre de soro para celulas de mamiferos
DE1993634097 DE69334097T2 (de)	1992-08-24	1993-08-24	Serumfreies Medium für Säugetierzellen
PT00117026T PT1045023E (pt)	1992-08-24	1993-08-24	Meio isento de soro
DK00117026T DK1045023T3 (da)	1992-08-24	1993-08-24	Serumfrit medium
EP20000117026 EP1045023B1 (fr)	1992-08-24	1993-08-24	Milieu exempt de sérum
AT93113502T ATE226632T1 (de)	1992-08-24	1993-08-24	Serumfreies medium für säugetierzellen
ES00117026T ES2274756T3 (es)	1992-08-24	1993-08-24	Medio sin suero.
EP19930113502 EP0584788B1 (fr)	1992-08-24	1993-08-24	Milieu exempt de sérum pour cellules de mammifères
AT00117026T ATE348147T1 (de)	1992-08-24	1993-08-24	Serumfreies medium
US08/111,428 US5641647A (en)	1992-08-24	1993-08-24	Serum free medium
AU44871/93A AU670957B2 (en)	1992-08-24	1993-08-24	Serum free medium
ZA936192A ZA936192B (en)	1992-08-24	1993-08-24	Serum free medium.
CY0700004A CY2572B1 (en)	1992-08-24	2007-02-09	Serum free medium

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL10292992A IL102929A (en)	1992-08-24	1992-08-24	Serum-free medium for mammalian cells

Publications (2)

Publication Number	Publication Date
IL102929A0 IL102929A0 (en)	1993-01-31
IL102929A true IL102929A (en)	1996-11-14

Family

ID=11063947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10292992A IL102929A (en)	1992-08-24	1992-08-24	Serum-free medium for mammalian cells

Country Status (13)

Country	Link
US (1)	US5641647A (fr)
EP (2)	EP0584788B1 (fr)
JP (1)	JP4124493B2 (fr)
AT (2)	ATE226632T1 (fr)
AU (1)	AU670957B2 (fr)
CA (1)	CA2104643C (fr)
CY (1)	CY2572B1 (fr)
DE (2)	DE69332430T2 (fr)
DK (2)	DK0584788T3 (fr)
ES (2)	ES2274756T3 (fr)
IL (1)	IL102929A (fr)
PT (2)	PT584788E (fr)
ZA (1)	ZA936192B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9303601D0 (sv) *	1993-11-01	1993-11-01	Kabi Pharmacia Ab	Improved cell cultivation method and medium
EP1482031B1 (fr) *	1996-08-30	2015-10-28	Life Technologies Corporation	Milieu de culture de cellules de mammifères exempt de sérum et son utilisation
US6692961B1 (en) *	1996-10-11	2004-02-17	Invitrogen Corporation	Defined systems for epithelial cell culture and use thereof
AU7637796A (en) *	1996-12-09	1998-07-03	James Edwin Bailey	Expression of active interferon beta 1 using recombinant rna replicons
SE9700983D0 (sv) *	1997-03-18	1997-03-18	Ascendia Ab	Stimulering, odling och preservation av pankreas- och andra celler
EP2295540A1 (fr) *	1998-11-19	2011-03-16	Organogenesis, Inc.	Constructions de tissu issues de la bioingénierie et leurs procédés de fabrication et d'utilisation
EP1754784A3 (fr) *	1999-09-03	2007-02-28	Applied Research Systems ARS Holding N.V.	Méthode permettant de produire une protéine secrétée hétérologue issue de cellules cho cultivées dans des microsupports
UA74557C2 (en) *	1999-09-03	2006-01-16	Applied Research Systems	A method for producing a heterologous secreted protein from chinese hamster ovaries cells grown on microcarriers
US7445924B2 (en)	2000-11-23	2008-11-04	Bavarian Nordic A/S	Modified Vaccinia Ankara virus variant and cultivation method
US6506576B2 (en)	2001-03-14	2003-01-14	Board Of Trustees Of The University Of Arkansas	Serum-and steroid-free culture media for cerebellar granule neurons
JP2005537793A (ja)	2002-09-05	2005-12-15	バヴァリアン・ノルディック・アクティーゼルスカブ	無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法
JP2009528843A (ja) *	2006-03-06	2009-08-13	ヒューマジーン・インコーポレイテッド	組換えヒトトロンビンおよびフィブリノゲンの調製法
US8415094B2 (en) *	2007-12-21	2013-04-09	Jaffar Ali bin M. Abdullah	Protein-free gamete and embryo handling and culture media products
CN103898123B (zh) *	2012-12-28	2019-03-15	北京韩美药品有限公司	重组人IFN-β-1a及其生产和纯化方法
CA2904146C (fr)	2013-03-08	2023-03-21	Neuclone Biologics Pty Ltd	Systeme d'expression cellulaire
AU2014225273A1 (en) *	2013-03-08	2015-09-24	Neuclone Biologics Pty Ltd	Cell culture media composition and methods of producing thereof
CN103484426B (zh) *	2013-10-15	2014-11-26	齐鲁制药有限公司	一种无动物源的低蛋白培养基
CN104593318B (zh) *	2013-10-31	2018-05-04	中国食品发酵工业研究院	一种用于细胞培养基的玉米活性肽添加剂
US9534026B2 (en)	2013-10-31	2017-01-03	China National Research Institute Of Food & Fermentation Industries	Corn active peptide additive for cell culture medium
JP7521738B2 (ja) *	2020-05-18	2024-07-24	キヤノン株式会社	目的細胞の生産方法、目的細胞による生産物の生産方法、および無血清培地

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU621972B2 (en) *	1988-12-14	1992-03-26	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Cell culture medium for human liver epithelial cell line
IL93463A0 (en) *	1989-02-27	1990-11-29	Lilly Co Eli	Improved tissue culture method
GB9022545D0 (en) *	1990-10-17	1990-11-28	Wellcome Found	Culture medium
US5256766A (en) *	1991-02-19	1993-10-26	The Regents Of The University Of California	Recombinant thrombin receptor and related pharmaceuticals

1992
- 1992-08-24 IL IL10292992A patent/IL102929A/en not_active IP Right Cessation
1993
- 1993-08-23 CA CA 2104643 patent/CA2104643C/fr not_active Expired - Lifetime
- 1993-08-23 JP JP20805393A patent/JP4124493B2/ja not_active Expired - Lifetime
- 1993-08-24 US US08/111,428 patent/US5641647A/en not_active Expired - Lifetime
- 1993-08-24 AU AU44871/93A patent/AU670957B2/en not_active Expired
- 1993-08-24 DK DK93113502T patent/DK0584788T3/da active
- 1993-08-24 DK DK00117026T patent/DK1045023T3/da active
- 1993-08-24 PT PT93113502T patent/PT584788E/pt unknown
- 1993-08-24 PT PT00117026T patent/PT1045023E/pt unknown
- 1993-08-24 ES ES00117026T patent/ES2274756T3/es not_active Expired - Lifetime
- 1993-08-24 DE DE69332430T patent/DE69332430T2/de not_active Expired - Lifetime
- 1993-08-24 ZA ZA936192A patent/ZA936192B/xx unknown
- 1993-08-24 AT AT93113502T patent/ATE226632T1/de active
- 1993-08-24 ES ES93113502T patent/ES2185618T3/es not_active Expired - Lifetime
- 1993-08-24 EP EP19930113502 patent/EP0584788B1/fr not_active Expired - Lifetime
- 1993-08-24 AT AT00117026T patent/ATE348147T1/de active
- 1993-08-24 EP EP20000117026 patent/EP1045023B1/fr not_active Expired - Lifetime
- 1993-08-24 DE DE1993634097 patent/DE69334097T2/de not_active Expired - Lifetime
2007
- 2007-02-09 CY CY0700004A patent/CY2572B1/xx unknown

Also Published As

Publication number	Publication date
PT584788E (pt)	2003-02-28
ES2185618T3 (es)	2003-05-01
JP4124493B2 (ja)	2008-07-23
IL102929A0 (en)	1993-01-31
EP1045023B1 (fr)	2006-12-13
DK0584788T3 (da)	2003-02-24
ZA936192B (en)	1994-03-22
EP0584788B1 (fr)	2002-10-23
DE69332430D1 (de)	2002-11-28
EP0584788A2 (fr)	1994-03-02
CA2104643C (fr)	2009-07-21
DE69332430T2 (de)	2003-07-17
EP1045023A1 (fr)	2000-10-18
JPH06153931A (ja)	1994-06-03
ATE226632T1 (de)	2002-11-15
DK1045023T3 (da)	2007-03-12
US5641647A (en)	1997-06-24
CY2572B1 (en)	2008-07-02
DE69334097D1 (de)	2007-01-25
ES2274756T3 (es)	2007-06-01
PT1045023E (pt)	2007-02-28
ATE348147T1 (de)	2007-01-15
DE69334097T2 (de)	2007-07-12
AU670957B2 (en)	1996-08-08
CA2104643A1 (fr)	1994-02-25
EP0584788A3 (fr)	1995-01-18
AU4487193A (en)	1994-03-03

Legal Events

Date	Code	Title
1997-04-15	FF	Patent granted
1997-07-13	KB	Patent renewed
1998-12-27	KB	Patent renewed
2002-09-12	KB	Patent renewed
2006-10-04	KB	Patent renewed
2010-11-30	KB	Patent renewed
2013-04-30	EXP	Patent expired

Publication	Publication Date	Title
EP1045023B1 (fr)	2006-12-13	Milieu exempt de sérum
US6667034B2 (en)	2003-12-23	Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture, methods for assaying the effect of substances on lineage-specific cell production, and cell compositions produced by these cultures
AU780791B2 (en)	2005-04-14	Medium for the protein-free and serum-free cultivation of cells
KR100496356B1 (ko)	2005-11-25	포유동물세포배양으로생산되는단백질의시알릴화조절방법
KR100616028B1 (ko)	2006-08-28	인자 ⅷ을 위한 발현 시스템
EP0422186B1 (fr)	1998-12-09	Utilisation de l'oncostatine m pour la suppression des antigenes mhc
EP0412149B1 (fr)	1995-11-08	Emploi d'il-7 dans des medicaments de stimulation de production de plaquettes
Migliaccio et al.	1988	Human embryonic hemopoiesis: control mechanisms underlying progenitor differentiation in vitro
Jungo et al.	2001	IFN-β inhibits the ability of t lymphocytes to induce TNF-α and IL-1β production in monocytes upon direct cell–cell contact
CA2271734A1 (fr)	1998-05-22	Cellules sensibles a tgf.beta.1 derivees de la moelle osseuse
US7531644B2 (en)	2009-05-12	IL-6 receptor•IL-6 direct fusion protein
CA2342859A1 (fr)	2000-03-16	Production d'erythropoietine humaine
Kadouri et al.	1992	Dynamic changes in cytokine secretion by stromal cells during prolonged maintenance under protein‐free conditions
Hosoi et al.	1991	Optimization of cell culture conditions for production of biologically active proteins
EP1094081B1 (fr)	2005-09-21	Proteine fusionnee avec liaison directe du recepteur il-6 a il-6
JP2751325B2 (ja)	1998-05-18	蛋白質の産生方法
Laouar et al.	1994	Protease‐catalyzed conversion of insulin‐like growth factor‐1 and interleukin‐6 into high‐molecular‐mass species through the sequential action of hematopoietic surface‐associated cathepsin G and γ‐glutamyl transpeptidase‐related activities
EP1318198B1 (fr)	2006-03-22	Procédé pour produire un polypeptide recombine comprenant l'addition d'un inhibiteur de chymotrypsines au milieu de culture cellulaire
Battista et al.	1993	Chinese Hamster Ovary (CHO) cell growth and recombinant protein production in serum-free media
WO1994018310A1 (fr)	1994-08-18	Additif de stimulation de croissance pour milieu de culture de cellules de mammifere